Pharmacological studies demonstrate that NGF applied as eye-drops (ed-NGF) can reach the posterior segment of the eye [7,11,12] and counteract the loss of retinal cells in animal model of retinopathy [13]. The gene discussed is NGF; the disease is retinal disorder.